Fractyl Health, Inc. (GUTS)
NASDAQ: GUTS · Real-Time Price · USD
1.880
-0.020 (-1.05%)
Jun 3, 2025, 1:16 PM - Market open
Fractyl Health Revenue
Fractyl Health had revenue of $60.00K in the twelve months ending March 31, 2025, down -59.46% year-over-year. In the year 2024, Fractyl Health had annual revenue of $93.00K, down -22.50%.
Revenue (ttm)
$60.00K
Revenue Growth
-59.46%
P/S Ratio
1,550.93
Revenue / Employee
$561
Employees
107
Market Cap
92.08M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
GUTS News
- 15 days ago - Fractyl Health Advances Rejuva® Gene Therapy Platform with Submission of First Clinical Trial Application Module in Europe for RJVA-001 in Type 2 Diabetes - GlobeNewsWire
- 17 days ago - Fractyl Health Unveils New Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Preclinical Data Highlighting Durable Potency and Safety with Limited Systemic GLP-1 Exposure at ASGCT 2025 - GlobeNewsWire
- 20 days ago - Forge Biologics Announces AAV Development and cGMP Manufacturing Relationship with Fractyl Health to Advance Their Gene Therapy Platform for Patients with Metabolic Diseases - Business Wire
- 20 days ago - Fractyl Health, Inc. (GUTS) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 20 days ago - Fractyl Health Announces First Quarter 2025 Financial Results and Business Updates - GlobeNewsWire
- 4 weeks ago - Fractyl Health to Report First Quarter 2025 Financial Results and Provide Business Updates on May 13, 2025, and Will Participate in an Upcoming Investor Conference - GlobeNewsWire
- 5 weeks ago - Fractyl Health to Present Compelling Preclinical Data from its Rejuva® Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting - GlobeNewsWire
- 2 months ago - Fractyl Health Reports Positive Early Data Showing Revita® Has Potential to Prevent Weight Regain After GLP-1 Discontinuation - GlobeNewsWire